About Evox

Based in Oxford, UK, Evox Therapeutics was founded in 2016 by Professor Matthew Wood of Oxford University and Associate Professor Samir EL Andaloussi and Dr Per Lundin of the Karolinska Institute, to capitalise on foundational intellectual property springing from the groundbreaking exosome research carried out in these two world-leading labs.

Backed by Oxford Sciences Innovation and with a driven, entrepreneurial and multidisciplinary team, Evox’s mission is to positively impact human health by creating novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families.